Copyright © 2025 Springer Healthcare Limited. Part of the Springer Nature Group.
CH_EM-115759
Many thanks to everyone, who attended the hybrid ASCO Direct™ GU Highlights Meeting on Friday, February 21, 2025.
The ASCO Direct™ GU Highlights Meeting was an educational program containing selected original sessions from the 2025 ASCO Genitourinary Cancers Symposium on prostate, renal cell and urothelial cancer. Attendees had the opportunity to view the original sessions and discuss the clinical relevance and implications for Swiss treatment landscape of study outcomes with their colleagues.
Here are the program and details of the ASCO Direct™ GU Highlights Meeting 2025. We look forward to organizing the ASCO Direct GU Highlights meeting 2026. The related information will be available later this year.
If you would like any further information, please feel free to contact us at [email protected]
The program is supervised by an independent scientific committee:
Onkozentrum Zürich
Claraspital Basel
GU Cancer Experts:
Friday, February 21, 2025, from 16:00 until 19:30
The meeting is CME accredited for the live participation (in person as well as virtual). 3 credits by SGU and SSMO.
ASCO DIRECT™ programs are officially licensed by the American Society of Clinical Oncology, Inc. (ASCO). Each presentation is provided solely for educational and informational purposes and personal use only. No part of any presentation may be edited or altered, or reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, nor may it be used for commercial purposes, without in each case the express written permission of ASCO. The ideas and opinions expressed in this presentation do not necessarily reflect those of ASCO. The mention of any company, product, service, or therapy does not constitute an endorsement of any kind by ASCO. It is the responsibility of the treating physician or other health care provider, relying on independent experience and knowledge of the patient, to determine drug dosages and the best treatment for the patient. Viewers are advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each drug to be administered to verify , among other matters, the dosage, the method and duration of administration, or contraindications. ASCO assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the material contained in this presentation or any errors or omissions. © 2025 American Society of Clinical Oncology, Inc. All rights reserved worldwide.